78 results match your criteria: "the Netherlands Cancer Institute (NKI)[Affiliation]"
Nucl Med Commun
January 2025
Urology Department, The Netherlands Cancer Institute (NKI), Antoni van Leeuwenhoek Hospital, Urology, Amsterdam, The Netherlands.
Objective: To evaluate the effect of prostate-specific membrane antigen (PSMA) PET/computed tomography (CT) on clinical decision-making of radical prostatectomy (RP) and pelvic lymph node dissection (PLND) after its utilization in daily clinical practice at an European high-volume cancer center.
Materials And Methods: Patients who had unfavorable intermediate- and high-risk prostate cancer between 2017 and 2021 were included retrospectively and divided into two groups; those who staged using PSMA PET/CT (group 1) and those who staged using conventional modalities (group 2). Clinical decision-making of RP over nonsurgical treatments and f PLND were primary endpoints and evaluated using regression models.
Radiother Oncol
December 2024
Catharina Hospital Eindhoven - department of radiation oncology, Eindhoven, The Netherlands; Eindhoven University of Technology - Department of Electrical Engineering and Department of Applied Physics and Science Education, Eindhoven, The Netherlands.
Background And Purpose: During the ESTRO 2023 physics workshop on "AI for the fully automated radiotherapy treatment chain", the topic of deep learning (DL) segmentation was discussed. Despite its widespread use in radiotherapy, the time needed to evaluate and correct DL segmentations remains burdensome. While segmentation uncertainty could be beneficial for clinicians, there is a lack of understanding on what information should be presented to ease their task.
View Article and Find Full Text PDFRadiother Oncol
December 2024
Department of Radiation Oncology, the Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands. Electronic address:
Introduction: The FLAME trial demonstrated that the dose to the gross tumor volume (GTV) is associated with tumour control in prostate cancer patients. This raises the question if dose de-escalation to the remaining prostate gland can be considered. Therefore, we investigated if intraprostatic recurrences occur at the location of the GTV and which dose was delivered at that location.
View Article and Find Full Text PDFTarget Oncol
September 2024
Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands.
Background: Atezolizumab is a programmed death-ligand 1 (PD-L1) checkpoint inhibitor for the treatment of different forms of cancer. The subcutaneous formulation of atezolizumab has recently received approval. However, treatment with atezolizumab continues to be expensive, and the number of patients needing treatment with this drug continues to increase.
View Article and Find Full Text PDFPract Radiat Oncol
November 2024
Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin.
Purpose: To provide a comprehensive review of the means by which to optimize target volume definition for the purposes of treatment planning for patients with intact prostate cancer with a specific emphasis on focal boost volume definition.
Methods: Here we conduct a narrative review of the available literature summarizing the current state of knowledge on optimizing target volume definition for the treatment of localized prostate cancer.
Results: Historically, the treatment of prostate cancer included a uniform prescription dose administered to the entire prostate with or without coverage of all or part of the seminal vesicles.
Int J Radiat Oncol Biol Phys
November 2024
Department of Radiation Medicine and Applied Sciences, UC San Diego School of Medicine, La Jolla, California; Department of Radiology, UC San Diego School of Medicine, La Jolla, California; Department of Bioengineering, UC San Diego Jacobs School of Engineering, La Jolla, California. Electronic address:
Purpose: The focal radiation therapy (RT) boost technique was shown in a phase III randomized controlled trial (RCT) to improve prostate cancer outcomes without increasing toxicity. This technique relies on the accurate delineation of prostate tumors on MRI. A recent prospective study evaluated radiation oncologists' accuracy when asked to delineate prostate tumors on MRI and demonstrated high variability in tumor contours.
View Article and Find Full Text PDFTarget Oncol
September 2024
Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
Background: The antibody-drug conjugate sacituzumab govitecan is approved for metastatic triple-negative breast cancer and has shown promising results in various other types of cancer. Its costs may limit patient access to this novel effective treatment modality.
Objective: The purpose of this study was to develop an evidence-based rational dosing regimen that results in targeted drug exposure within the therapeutic range while minimizing financial toxicity, to improve treatment access.
BMC Oral Health
May 2024
Non‑Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
BMC Oral Health
January 2024
Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Breast Cancer Res
November 2023
Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
Background: Invasive breast cancer patients are increasingly being treated with neoadjuvant chemotherapy; however, only a fraction of the patients respond to it completely. To prevent overtreatment, there is an urgent need for biomarkers to predict treatment response before administering the therapy.
Methods: In this retrospective study, we developed hypothesis-driven interpretable biomarkers based on deep learning, to predict the pathological complete response (pCR, i.
J Laparoendosc Adv Surg Tech A
January 2024
Department of Urology, Cerrahpaşa Medical Faculty, İstanbul University-Cerrahpaşa, İstanbul, Turkey.
The aim of this study was (1) to explore effect of ureteral access sheath (UAS) use on primary retrograde intrarenal surgery (RIRS) outcomes, short-term kidney functions, radiation exposure, and ureteroscope lifetime (URS-LT) and (2) to reveal factors that predict UAS insertion failure. Patients ( = 1318) who underwent RIRS without UAS (Group 1), those who had operation with a <11-13 Fr (Group 2), and those with a ≥11-13 Fr UAS were matched (1:1:2) and compared. Stone-free rate (SFR), intra- and postoperative complications, acute kidney injury (AKI), fluoroscopy time, URS-LT, and UAS insertion failure were the outcomes.
View Article and Find Full Text PDFInt J Radiat Oncol Biol Phys
January 2024
Department of Radiation Oncology, The Netherlands Cancer Institute (NKI-AVL), Amsterdam, The Netherlands. Electronic address:
Purpose: The FLAME trial (NCT01168479) showed that isotoxic focal boosting to the intraprostatic lesion(s) in patients with intermediate- and high-risk prostate cancer improves 5-year disease-free survival (DFS). Although the near-minimum dose to the gross tumor volume (D98%) was associated with improved outcomes, a closer look suggested that this might not be the same for all patients. Therefore, we investigated whether risk factors that are associated with a benefit of focal boosting can be identified.
View Article and Find Full Text PDFMicrovasc Res
January 2024
Amsterdam University Medical Centers location University of Amsterdam, Dept. of Obstetrics and Gynecology, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Reproduction and Development Research Institute, Amsterdam, the Netherlands.
Background: Ninety percent of cervical cancer (CC) diagnoses and deaths occur in low and middle-income countries (LMICs). Especially in these countries, where human and material resources are limited, there is a need for real-time screening methods that enable immediate treatment decisions (i.e.
View Article and Find Full Text PDFCancer Causes Control
December 2023
Urology, The Netherlands Cancer Institute (NKI), Antoni Van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Purpose: The aim of this study was to reveal the association between the other-cause mortality (OCM) and post-radical prostatectomy (RP) salvage radiotherapy (sRT) in men with prostate cancer (PCa).
Methods: A retrospective study was carried out with patients who had PCa and underwent RP ± sRT in a high-volume cancer center between 2005 and February 2019. Data from 1955 patients were subjected to a 1:1 matching for age, initial PSA, pathological (p)T/N stages, and ISUP score, which yielding 439 RP + RT (group 1) vs 439 RP-only cases (group 2), without any residual difference.
Front Public Health
July 2023
Tufts Medical Center, Institute for Clinical Research and Health Policy Studies, Boston, MA, United States.
Introduction: Due to insufficient data on patient experience with healthcare system among patients with chronic obstructive pulmonary disease (COPD), particularly in developing countries, this study attempted to investigate the journey of patients with COPD in the healthcare system using nationally representative data in Iran.
Methods: This nationally representative demonstration study was conducted from 2016 to 2018 using a novel machine-learning based sampling method based on different districts' healthcare structures and outcome data. Pulmonologists confirmed eligible participants and nurses recruited and followed them up for 3 months/in 4 visits.
Target Oncol
May 2023
Department of Pharmacy, Radboud University Medical Center, Radboud Institute for Health Sciences, Geert Grooteplein Zuid 10, 6525GA, Nijmegen, The Netherlands.
Background: Expensive novel anticancer drugs put a serious strain on healthcare budgets, and the associated drug expenses limit access to life-saving treatments worldwide.
Objective: We aimed to develop alternative dosing regimens to reduce drug expenses.
Methods: We developed alternative dosing regimens for the following monoclonal antibodies used for the treatment of lung cancer: amivantamab, atezolizumab, bevacizumab, durvalumab, ipilimumab, nivolumab, pembrolizumab, and ramucirumab; and for the antibody-drug conjugate trastuzumab deruxtecan.
Front Endocrinol (Lausanne)
April 2023
Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, United States.
Aims: To investigate the journey of patients with diabetes in the healthcare system using nationally-representative patient-reported data.
Methods: Participants were recruited using a machine-learning-based sampling method based on healthcare structures and medical outcome data and were followed up for three months. We assessed the resource utilization, direct/indirect costs, and quality of healthcare services.
EJNMMI Radiopharm Chem
November 2022
Department of Radiology and Nuclear Medicine, Erasmus MC, 3015 CN, Rotterdam, The Netherlands.
Background: Radiopharmaceuticals are considered as regular medicinal products and therefore the same regulations as for non-radioactive medicinal products apply. However, specific aspects should be considered due to the radiochemical properties. Radiopharmaceutical dedicated monographs are developed in the European Pharmacopoeia to address this.
View Article and Find Full Text PDFPLoS One
August 2022
Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Diagnostics (Basel)
July 2022
Department of Medical Imaging, Radboudumc, 6525 GA Nijmegen, The Netherlands.
Automatic breast and fibro-glandular tissue (FGT) segmentation in breast MRI allows for the efficient and accurate calculation of breast density. The U-Net architecture, either 2D or 3D, has already been shown to be effective at addressing the segmentation problem in breast MRI. However, the lack of publicly available datasets for this task has forced several authors to rely on internal datasets composed of either acquisitions without fat suppression (WOFS) or with fat suppression (FS), limiting the generalization of the approach.
View Article and Find Full Text PDFRadiother Oncol
September 2022
Department of Radiation Oncology, University Hospitals Leuven, Belgium.
Mol Oncol
June 2022
Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, USA.
Primary clear cell renal cell carcinoma (ccRCC) has been previously characterized, but the genomic landscape of metastatic ccRCC is largely unexplored. Here, we performed whole exome sequencing (WES) in 68 samples from 44 patients with ccRCC, including 52 samples from a metastatic site. SETD2, PBRM1, APC and VHL were the most frequently mutated genes in the metastatic ccRCC cohort.
View Article and Find Full Text PDFEur J Surg Oncol
June 2022
Sarcoma and Melanoma Unit, Royal Marsden Hospital NHS Trust: Royal Marsden NHS Foundation Trust, 237 Fulham Road, London, SW3 6JJ, UK; Melanoma and Sarcoma Unit, Department of Academic Surgery Royal Marsden Hospital, London, SW3 6JJ, UK. Electronic address:
Background: Prior to the advent of effective systemic therapy for melanoma, isolated limb perfusion (ILP) was the most effective local treatment for advanced in-transit melanoma (ITM). However, many patients who are now treated by ILP will have received prior immunotherapy. We sought to compare response rates to ILP in patients who had previously received immunotherapy compared to immunotherapy naive patients.
View Article and Find Full Text PDFOral Oncol
February 2022
Department of Otolaryngology-Head and Neck Surgery, Amsterdam UMC, Amsterdam, the Netherlands.
Introduction: The aim was to analyse prognosticators in acinic cell carcinoma (AciCC) in two head and neck referral centers in Amsterdam, the Netherlands.
Materials And Methods: Eighty- nine cases of AciCC treated between 1979 and 2016 were retrospectively reviewed. Five, - 10 -and 20- year estimates of survival were executed as well as univariate analysis of prognosticators.
ESMO Open
December 2021
Universidad de Alcalá, Medical Oncology Department, IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Background: Exploratory research showed that female oncologists are frequently under-represented in leadership roles. European Society for Medical Oncology (ESMO) Women for Oncology (W4O) therefore implemented gender equality programs in career development and established international studies on female representation at all stages of the oncology career pathway.
Methods: For 2017-2019, data were collected on (i) first and last authorship of publications in five major oncology journals and (ii) representation of women in leadership positions in oncology-as invited speakers at National/International congresses, board members or presidents of National/International societies and ESMO members.